Pantoprazole is a selective proton pump inhibitor drug (PPI) used for short-term treatment of erosion and ulceration of the esophagus caused by Gastroesophageal reflux disease. It acts by inhibiting the secretion of hydrochloric acid in the stomach by specific action on proton pumps of parietal cells.
Why is this medication prescribed?Pantoprazole is used to treat certain conditions in which there is too much acid in the stomach. It is used to treat erosive esophagitis or "heartburn" caused by gastroesophageal reflux disease (GERD), a condition where the acid in the stomach washes back up into the esophagus. This medicine may also be used to treat Zollinger-Ellison syndrome, a condition where the stomach produces too much acid.
Indications and Usage
- Duodenal ulcer
- Gastric ulcer
- Gastro-esophageal reflux disease
- Moderate and severe reflex oesophagitis
- Zollinger-Ellison syndrome and other hypersecretory conditions
- Prevention of gastro duodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs).
Mechanism of Action:Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).
Pharmacokinetics:Absorption: Rapidly absorbed. However, absorption may be delayed up to 2 hours or more if pantoprazole is taken with food.
Bioavailability (oral)- 77%.
Distribution: VolD - Following intravenous administration to extensive metabolizers: 0.17 L per kg (11 to 23.6 L).
Protein Binding: Very high (98%); primarily to albumin.
Half-Life: Elimination - Following oral or intravenous administration: 1 hour.
The half-life of pantoprazole is prolonged (7 to 9 hours) in patients with cirrhosis of the liver and in genetically determined slow metabolizers (3.5 to 10 hours).
Pantoprazole tablets may influence the effectiveness of other medicines, so tell your doctor if you are taking
● Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer) because Pantoprazole tablets may stop these and other medicines from working properly.
● Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.
● Atazanavir (used to treat HIV-infection).
Pregnancy and Breast-feeding:
There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported. If you are pregnant, or think you may be pregnant, or if you are breast-feeding, you should use this medicine only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.
● Neurologic: headache (5%)
● Chest pain, headache, nausea, pain, anxiety
Symptomatic response does not preclude presence of gastric malignancy
Atrophic gastritis has been noted with long-term therapy
Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. Hypomagnesemia has been reported rarely with prolonged treatment with PPIs
Oral:Gastroesophageal reflux disease (treatment) Oral, 40 mg per day for up to eight weeks. An additional eight-week course may be considered in patients who have not healed after four to eight weeks of treatment.
Disclaimer:To be taken only after consulting with the doctor.